DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF TRANSPLANT- INELIGIBLE (TIE) PATIENTS IN THE PHASE 3 CEPHEUS STUDY T Facon; S Zweegman; V Hungria; NJ Bahlis; CP Venner; M Braunstein; L Pour; J Marti; A Maiolino; SZ Usmani;

REMISSÃO E SOBREVIDA DE LONGO PRAZO (¿5 ANOS) APÓS TRATAMENTO COM CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) EM PACIENTES DO CARTITUDE-1 COM MIELOMA MÚLTIPLO RECIDIVADO/REFRATÁRIO (RRMM) T Queiroz; P Voorhees; TG Martin; Y Lin; AD Cohen; M Htut; M Agha; J Berdeja; B Dhakal; J Sundar;

CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS RECEIVING VENETOCLAX-BASED REGIMENS IN BRAZIL: A REAL-WORLD STUDY A Costa; RLR Baptista; M Guaraná; MPQ Neto; AA Johann; VA Mauad; C Chiattone; E Fagundes; FB Duarte; E Nunes; M Dibai; M Nucci;